Biotech valuations rise post-FDA leadership change

After the FDA chief's appointment, biotech stocks will surge by 10% or more within 30 days due to improved regulatory clarity. Investors will anticipate faster drug approvals and fewer rejections.

Implied probability (Yes)

60%